NEW YORK (Reuters Health) - Type 2 diabetics who have certain adiponectin polymorphisms appear to have less improvement in glucose control in response to rosiglitazone, Korean researchers report in the May issue of Diabetes Care.
“We found that variations in the adiponectin gene could affect the rosiglitazone treatment response to the serum adiponectin level and blood glucose control,” lead investigator Dr. Eun Seok Kang told Reuters Health
Dr. Kang of Yonsei University School of Medicine, Seoul and colleagues studied 166 patients with type 2 diabetes who were treated with rosiglitazone 4 mg per day for 12 weeks.
Compared with patients with other genotypes, carriers of the GG genotype of the single nucleotide polymorphism (SNP) 45 of the adiponectin gene had a smaller reduction in fasting plasma glucose levels and HbA1c values. There also was a significantly smaller increase in serum adiponectin concentration in this group.
In addition, carriers of the GG genotype of SNP276 showed less reduction in fasting glucose levels than did other patients.
Overall, those with the GG homozygote haplotype showed less response than did patients with other haplotypes.
Thus, concluded Dr. Kang, “these findings might be clinically relevant in the prediction of patients who will respond best to rosiglitazone treatment.”
Source: Diabetes Care 2005;28:1139-1144. [ Google search on this article ]
Copyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
